| Multiple Sclerosis, Relapsing-Remitting
Ocrevus vs Plegridy
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Ocrevus vs Plegridy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPlegridy has a higher rate of injection site reactions vs Ocrevus based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Plegridy but not Ocrevus, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ocrevus
Plegridy
At A Glance
IV infusion
Every 6 months
CD20 antagonist
SC or IM injection
Every 14 days
Interferon beta-1a (pegylated)
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive Initial dose: 300 mg IV infusion, followed two weeks later by a second 300 mg IV infusion; subsequent doses: 600 mg IV infusion every 6 months.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Titrate from 63 mcg SC or IM on day 1, 94 mcg on day 15, to a full maintenance dose of 125 mcg every 14 days starting day 29.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to OCREVUS
- History of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY
Adverse Reactions
Most common (>=10%) Upper respiratory tract infections, infusion reactions, skin infections, lower respiratory tract infections
Serious Infusion reactions, infections, progressive multifocal leukoencephalopathy, reduction in immunoglobulins, malignancies, immune-mediated colitis, liver injury
Postmarketing Immune-mediated colitis, liver injury, serious herpes infections, progressive multifocal leukoencephalopathy, babesiosis, pyoderma gangrenosum
Most common (>=10%) Injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, arthralgia
Serious Hepatic injury, depression and suicide, anaphylaxis and other allergic reactions, injection site reactions including necrosis, congestive heart failure, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, autoimmune disorders, seizures
Postmarketing Anaphylactic reactions, hepatic injury (including noninfectious hepatitis), pulmonary arterial hypertension
Pharmacology
CD20 antagonist; ocrelizumab is a recombinant humanized IgG1 monoclonal antibody that binds to CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis.
Pegylated recombinant interferon beta-1a; the mechanism by which PLEGRIDY exerts its clinical effects in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ocrevus
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Plegridy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Ocrevus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Plegridy
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Ocrevus
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Plegridy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OcrevusView full Ocrevus profile
PlegridyView full Plegridy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.